Sildenafil for Early Pulmonary Vascular Disease in Scleroderma (SEPVADIS)

This is a Phase II randomized, double-blind, placebo-controlled trial of sildenafil in men and women with Scleroderma with mildly elevated pulmonary pressures (SSc-MEP) to determine whether sildenafil may be an effective treatment for SSc-MEP.

Study Overview

• Status: Recruiting
• Conditions: Scleroderma; Mildly Elevated Pulmonary Pressures
• Intervention / Treatment: Drug: Sildenafil; Other: Placebo

Detailed Description

Data shows that sildenafil (SIL) is an effective therapy in SSc-PAH. SIL has been safely used in many patients with various vascular and cardiovascular diseases over the past three decades. Randomized controlled trial data for SIL shows improvement in 6MWD, hemodynamics, and even evidence of cardiac remodeling in PAH and SSc-PAH patients. Based upon these data, SIL may be an effective therapy in SSc-MEP. This study will help determine whether sildenafil could be a good treatment for patients with scleroderma that have mildly elevated pulmonary pressures.

• Study Type: Interventional
• Enrollment (Estimated): 30
• Phase: Phase 2

Contacts and Locations

• Study Contact: Name: Stephen Mathai, MD; Phone Number: 4106146311; Email: smathai4@jhmi.edu
• Study Contact Backup: Name: Dezeray Dutton; Phone Number: 4435078222; Email: dcephas1@jhu.edu

Study Locations

• United States
  • Louisiana
    • New Orleans, Louisiana, United States, 70806
      • Not yet recruiting
      • Louisiana State University
      • Principal Investigator: Matthew Lammi, MD
      • Contact: Matthew Lammi, MD; Phone Number: 504-568-4634
      • Contact: Marie Sandi; Email: mchild@lsuhsc.edu
  • Maryland
    • Baltimore, Maryland, United States, 21287
      • Recruiting
      • Johns Hopkins
      • Contact: Dezeray Dutton; Phone Number: 4435078222; Email: dcephas1@jhu.edu
      • Contact: Stephen Mathai, MD; Phone Number: 410-614-6311; Email: smathai4@jhmi.edu
      • Principal Investigator: Stephen Mathai, MD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 16 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Previous documentation of mean pulmonary artery pressure between 21 and 24 mm Hg with a pulmonary capillary wedge pressure (or left ventricular end-diastolic pressure) ≤ 15 mm Hg within six months before study entry.
• Diagnosis of SSc according to 2013 American College of Rheumatology/ European League Against Rheumatism (ACR/EULAR) classification criteria.
• Pulmonary function tests with forced expiratory volume in one second/forced vital capacity (FEV1/FVC) >50% AND either a) total lung capacity (TLC) or forced vital capacity (FVC) > 70% predicted or b) TLC or FVC between 60% and 70% predicted with no more than mild interstitial lung disease on computerized tomography scan of the chest on studies obtained within 6 months of enrollment.
• Ventilation perfusion scan or computed tomography with intravenous contrast (CT angiogram) without evidence of chronic thromboembolism at anytime before study entry.
• Ability to perform six minute walk testing without significant limitations in musculoskeletal function or coordination.
• Informed consent.

Exclusion Criteria:

• World Health Organization (WHO) Class IV functional status.
• Systolic blood pressure less than 90 mmHg at screening visit prior to enrollment.
• Clinically significant untreated sleep apnea.
• Left-sided valvular disease (more than moderate mitral valve stenosis or insufficiency or aortic stenosis or insufficiency), pulmonary artery or valve stenosis, or ejection fraction < 45% on most recent echocardiography (within 1 year).
• Use of Pulmonary Arterial Hypertension (PAH) therapy (prostacyclin analogues, endothelin-1 receptor antagonists,phosphodiesterase-5 inhibitors, riociguat, selexipag) within the past 3 months.
• Hospitalized or acutely ill.
• Renal failure (creatinine above 2.0) at screening visit.
• Enrollment in a clinical trial or concurrent use of another investigational drug (non FDA approved) or device therapy within 30 days of screening visit.
• Age < 18.
• Currently pregnant.
• Current use of nitrates.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Sildenafil; Sildenafil 20 mg by mouth three(3) times each day	Drug: Sildenafil; Sildenafil 20 mg three times a day. This is the approved dose for the treatment of pulmonary arterial hypertension. It is being studied in this trial with a population who has mildly elevated pulmonary pressures.; Other Names: Revatio, Viagra
Placebo Comparator: Placebo; Placebo by mouth three(3) times each day	Other: Placebo; Oral pill placebo.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Difference in change in distance walked in 6 minute walk test (6MWT) at 4 months	As assessed by change in 6 minute walk distance (6MWD) in feet (from baseline to 4 months) between the sildenafil group and the placebo group.	Baseline and 4 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Difference in change in distance walked in 6MWT at 12 months	As assessed by change in 6 minute walk test distance in feet (from baseline to 12 months) between the sildenafil group and the placebo group.	Baseline and 12 months
Difference in change in right ventricular function as assessed by cardiac MRI	As assessed by change in right ventricular function (normal/abnormal) on cardiac MRI.	Baseline and 4 months
Difference in change in right ventricular function as assessed by cardiac MRI	As assessed by change in right ventricular function (normal/abnormal) on cardiac MRI.	Baseline and 12 months
Difference in change in right ventricular function as assessed by invasive hemodynamics	As assessed by change in right ventricular function (normal/abnormal) on invasive hemodynamics.	Baseline and 4 months
Difference in change in right ventricular function as assessed by invasive hemodynamics	As assessed by change in right ventricular function (normal/abnormal) on invasive hemodynamics.	Baseline and 12 months
Difference in change in right ventricular function as assessed by echocardiography	As assessed by change in right ventricular function (normal/abnormal) on echocardiography.	Baseline and 4 months
Difference in change in right ventricular function as assessed by echocardiography	As assessed by change in right ventricular function (normal/abnormal) on echocardiography.	Baseline and 12 months
Difference in change in N-terminal pro b-type natriuretic peptide level	As assessed by changes in plasma N-terminal pro b-type natriuretic peptide (NT-proBNP) level (pg/mL) between sildenafil and placebo groups at four months and twelve months.	Baseline, 4 months and 12 months
Difference in change in health related quality of life as assessed by the 36-Item Short Form Health Survey (SF36) questionnaire	As assessed by changes in SF36 questionnaire between sildenafil and placebo groups at four months and twelve months. The SF36 yields a set of scaled scores in 8 domains, with higher numbers representing a better quality of life. Each scale is scored on a 0 to 100 range so that the lowest and highest possible scores are 0 and 100, respectively. Scores represent the percentage of total possible score achieved. In step 2, items in the same scale are averaged together to create the 8 scale scores. Items that are left blank (missing data) are not taken into account when calculating the scale scores. Hence, scale scores represent the average for all items in the scale that the respondent answered.	Baseline, 4 months and 12 months
Difference in change in health related quality of life as assessed by the emPHasis-10 health-related quality of life questionnaire (emPHasis-10).	As assessed by changes in emPHasis-10 questionnaire between sildenafil and placebo groups. The Emphasis 10 score consists of 10 questions scored in a semantic 6-point scale (from 0 to 5), for a total maximum score of 50 (the higher the score, the worse the quality of life).	Baseline, 4 months and 12 months
Difference in safety profile as assessed by frequency of adverse events	As assessed by frequency of adverse events between sildenafil and placebo groups.	Ongoing until study closes, up to 4 years
Difference in safety profile as assessed by severity of adverse events	As assessed by severity of adverse events between sildenafil and placebo groups.	Ongoing until study closes, up to 4 years

Collaborators and Investigators

• Sponsor: Johns Hopkins University
• Collaborators: Louisiana State University Health Sciences Center in New Orleans
• Investigators: Principal Investigator: Stephen Mathai, MD, Johns Hopkins University

Study record dates

Study Major Dates

• Study Start (Actual): September 20, 2021
• Primary Completion (Estimated): September 1, 2024
• Study Completion (Estimated): September 1, 2024

Study Registration Dates

• First Submitted: March 11, 2021
• First Submitted That Met QC Criteria: March 11, 2021
• First Posted (Actual): March 15, 2021

Study Record Updates

• Last Update Posted (Actual): September 14, 2023
• Last Update Submitted That Met QC Criteria: September 12, 2023
• Last Verified: September 1, 2023

More Information

Terms related to this study

• Keywords: SSc-MEP
• Additional Relevant MeSH Terms: Cardiovascular Diseases; Skin Diseases; Connective Tissue Diseases; Vascular Diseases; Scleroderma, Systemic; Scleroderma, Diffuse; Scleroderma, Localized; Molecular Mechanisms of Pharmacological Action; Vasodilator Agents; Urological Agents; Enzyme Inhibitors; Phosphodiesterase Inhibitors; Phosphodiesterase 5 Inhibitors; Sildenafil Citrate
• Other Study ID Numbers: IRB00265164

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No